Business Wire

GA-EMORY-UNIVERSITY

3.6.2016 19:51:54 CEST | Business Wire | Press release

Share
Internationally Acclaimed Public Health Researcher and Academic Leader Claire E. Sterk Named Emory University’s Next President

The Emory University Board of Trustees announced today that Claire E. Sterk, provost and executive vice president for academic affairs at Emory, has been selected as the university’s 20th president. She was elected by a unanimous vote of the trustees during its meeting in Atlanta.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160603005802/en/

Sterk has been a member of the Emory community since 1995, when she was appointed to the faculty of the Rollins School of Public Health. During her tenure at Emory, she has served as the Charles Howard Candler Professor of Public Health, chair of the Department of Behavioral Sciences and Health Education, associate dean for research, and senior vice provost for academic affairs. She was named provost and executive vice president for academic affairs in 2013.

Sterk will assume the role on September 1. She will succeed James W. Wagner, who announced in September 2015 his intention to retire at the end of August 2016 after 13 years as president.

“Claire Sterk is a confident leader, an accomplished academic administrator, and a respected researcher,” says John Morgan, chair of the Emory University Board of Trustees and chair of the Presidential Selection Committee. “She has a sophisticated knowledge and understanding of Emory and is passionate about leveraging Emory’s considerable strengths and assets to enhance its global reputation and reach.”

Sterk was the unanimous choice presented to the Board of Trustees by a 15-member Presidential Selection Committee that has dedicated the past six months to an intensive national and international search.

“I am deeply grateful to the trustees for this extraordinary opportunity to serve as Emory’s president,” says Sterk. “Emory has earned its place among the world’s premier comprehensive research universities, and is well known for its undergraduate, graduate, and professional education; its leadership in research and scholarship across all disciplines; and an unsurpassed culture of innovation and collaboration. I look forward to engaging with all members of the Emory community to develop a shared vision for future success.”

Sterk is the first woman to serve as president of Emory. She is a native of the Netherlands, where she earned her Ph.D. in sociology from Erasmus University in Rotterdam and her doctorandus degree in medical anthropology from the University of Utrecht.

At Emory, Sterk has held faculty appointments in anthropology; sociology; and women, gender, and sexuality studies. Her primary research interests are addiction, mental health, and HIV/AIDS, with a focus on community-based interventions. She is a leading international figure in the fields of public health and anthropology and the author of three books and more than 100 articles and book chapters.

In addition to service on numerous editorial boards, Sterk has held several professional leadership positions, including president of the Alcohol, Drug, and Tobacco section of the American Sociological Association and a board member of the Society for Applied Anthropology.

Sterk’s husband and research partner, Kirk Elifson, serves on the faculty of the Rollins School of Public Health. Together, they have attracted more than $33 million in external research funding to Emory.

Emory University (http://www.emory.edu ) is known for its demanding academics, outstanding undergraduate experience, highly ranked professional schools and state-of-the-art research facilities. Emory encompasses nine academic divisions as well as The Carter Center, the Yerkes National Primate Research Center, the Michael C. Carlos Museum, and Emory Healthcare, Georgia’s largest and most comprehensive health care system.

Contact:

Emory University
Nancy Seideman, 404-727-0640
Associate Vice President, Media Relations
nancy.seideman@emory.edu

Link:

ClickThru

Social Media:

https://www.facebook.com/EmoryUniversity

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye